[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 167
Citations 0
In This Issue of JAMA Dermatology
February 2020


JAMA Dermatol. 2020;156(2):111. doi:10.1001/jamadermatol.2019.2999

In this longitudinal cohort study, Meyer Sauteur and colleagues examined the frequency and clinical presentation of Mycoplasma pneumoniae–induced mucocutaneous disease in 152 children with community-acquired pneumonia (CAP). Results showed that mucocutaneous disease occurred much more frequently in children with CAP due to M pneumoniae than in those with CAP of other origins. Mucocutaneous disease was associated with increased systemic inflammation, morbidity, and a higher risk of long-term sequelae. Ramien and Bruckner provide an Editorial.


Dey and colleagues performed a cohort study at the National Institutes of Health to assess the association of soluble lectinlike oxidized low-density lipoprotein receptor-1 (sLOX-1) levels with accelerated noncalcified coronary burden in patients with psoriasis. They evaluated 175 patients using an enzyme-linked immunosorbent assay and coronary computed tomography angiography. Results suggest that a reduction in sLOX-1 level at 1 year is associated with improvements in patients with psoriasis, demonstrating the potential role of sLOX-1 in inflammatory atherogenesis in this skin condition.